[Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges]

Internist (Berl). 2019 Apr;60(4):399-404. doi: 10.1007/s00108-019-0578-7.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Germany
  • Humans
  • Orphan Drug Production*
  • Societies, Medical